18 citations
,
August 1985 in “European journal of endocrinology” Cyproterone acetate is effective for treating hirsutism, but some patients may feel worse on low-dose maintenance therapy.
January 2023 in “International Journal of Trichology” Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
1 citations
,
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes modest feminization in transgender female adolescents, and works better with added estrogens.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
October 2024 in “Asian Journal of Pharmaceutical and Clinical Research” Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.
14 citations
,
January 2008 in “Dermatology Online Journal” Hormonal therapies like cyproterone acetate and spironolactone may help some women with hair loss, but finasteride 1mg is not useful, and the effectiveness of other treatments is still unclear.
1 citations
,
January 2009 in “X-ray Structure Analysis Online” A new compound was made that might help treat diseases related to male hormones.
November 2024 in “International Journal of Scientific Reports” Dienogest is safer and has fewer side effects than GnRH analogues for treating endometriosis.
4 citations
,
September 2010 in “Medical Hypotheses”
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
14 citations
,
September 2015 in “Expert Opinion on Therapeutic Targets” The conclusion is that while oral contraceptive pills are effective for PCOS-related high androgen levels, new treatments with fewer side effects are needed.
26 citations
,
June 2003 in “PubMed” Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.
9 citations
,
April 2018 in “JAMA Dermatology” Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.
Diane and Androcur 10 improved acne and seborrhea in most women, and hirsutism and alopecia in about half.
7 citations
,
March 2013 in “Tetrahedron Letters” New method makes important drug ingredients more easily without needing extra purification steps.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for managing PCOS-related risks.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
1 citations
,
April 2024 in “Anais Brasileiros de Dermatologia” October 2014 in “Cancer research” Blocking mTORC1 reduces skin tumor growth in mice.
4 citations
,
February 2018 in “World journal of surgical oncology” A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
Ovulation inhibitors effectively treat menstrual issues and improve fertility but can have side effects.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
16 citations
,
September 1990 in “Fertility and sterility” Ketoconazole can treat ovarian hyperandrogenism but should be used cautiously with monitoring and birth control.
1 citations
,
November 2024 in “Neuro-Oncology” Temozolomide can cause severe bone marrow suppression, leading to life-threatening complications.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
5 citations
,
January 2016 in “International Journal of Trichology” Erlotinib can cause hair loss and texture changes.